12 results
ARS
2022 FY
PNT
POINT Biopharma Global Inc.
1 May 23
Annual report to shareholders
1:52pm
an ARPI switch to avoid the increasingly toxic profile of chemotherapy. Two recent studies have shown that, when patients are switched to a second-line
8-K
EX-1.1
PNT
POINT Biopharma Global Inc.
14 Sep 22
POINT Biopharma Prices Public Offering of Common Stock
4:14pm
, disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants (“Environmental Laws”) applicable to such entity, which … or release of hazardous or toxic substances or wastes, pollutants or contaminants. Except as described in the Registration Statement, the Time of Sale
S-3
EX-1.2
PNT
POINT Biopharma Global Inc.
1 Jul 22
Shelf registration
4:13pm
, the environment, or natural resources, or to use, handling, storage, manufacturing, transportation, treatment, discharge, disposal or release of hazardous or toxic … Laws, or of any actual or potential liability for or other obligation concerning the presence, disposal or release of hazardous or toxic substances
424B3
PNT
POINT Biopharma Global Inc.
31 Mar 22
Prospectus supplement
11:42am
failure of ARAT therapy. In spite of progression while on ARAT, a majority of patients are offered an ARAT switch to avoid the increasingly toxic
POS AM
PNT
POINT Biopharma Global Inc.
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
of patients are offered an ARAT switch to avoid the increasingly toxic profile of chemotherapy. Two recent studies have shown that, when patients
424B3
nc0utj6x1 6glc
5 Aug 21
Prospectus supplement
4:26pm
S-4
yf1491e
22 Mar 21
Registration of securities issued in business combination transactions
9:52pm
S-4
EX-10.17
qb3fetc6p37878y xcu
22 Mar 21
Registration of securities issued in business combination transactions
9:52pm
8-K/A
EX-2.1
twkfe it15j4pv6ku2qm
18 Mar 21
Financial Statements and Exhibits
9:08am
- Prev
- 1
- Next